Khat consumption: a pharmacological review

https://doi.org/10.1016/0376-8716(89)90029-XGet rights and content

Abstract

The present review deals with the considerable body of evidence gathered in the last ten years on the clinical and experimental pharmacology of Khat. Khat effects are generally agreed to be of amphetamine-like type. In particular, Khat ingestion, like amphetamine ingestion, produces sympathetic activation, anorexia, euphoria, increased intellectual efficiency and alertness. These effects are mainly mediated by phenylalkylamines, such as cathinone and cathine, because the pharmacological actions of these agents and those produced by amphetamine almost overlap. In infra-human species cathinone is an effective positive reinforcer (i.e., it maintains self-administration). However, it would be inappropriate to infer from cathinone and cathine effects assessed in animals a high potential of abuse for Khat in humans; apart from other reasons the bulk volume of Khat leaves, limits the ingestion of high quantities of the active principles. Accordingly, in habitual consumers Khat dependence is probably mild, because craving and tolerance to the sympathomimetic and neuroendocrine effects of Khat are present, but there is no definite abstinence syndrome. Therefore, in our opinion, policies restricting the use of Khat should be adopted with caution, lest they simply change the pattern of drug abuse and increase the spread of more dangerous drugs.

References (94)

  • A. Krikorian

    J. Ethnopharmacol.

    (1984)
  • S. Geisshusler et al.

    J. Ethnopharmacol.

    (1987)
  • P. Nencini et al.

    Drug Alcohol Depend.

    (1986)
  • A.S. Elmi

    J. Ethnopharmacol.

    (1983)
  • S.P. Gough et al.

    Lancet

    (1984)
  • C.K. Maitai et al.

    J. Pharm. Sci.

    (1975)
  • B. Kristiansson et al.

    J. Ethnopharmacol.

    (1987)
  • P. Kalix

    Eur. J. Pharmacol.

    (1980)
  • G.C. Wagner et al.

    Drug Alcohol Depend.

    (1982)
  • P. Kalix

    Neuropharmacology

    (1986)
  • P. Kalix

    Prog. Neuropsychopharmacol. Biol. Psychiatr.

    (1982)
  • J.L. Zelger et al.

    Neuropharmacology

    (1981)
  • G.P. Mereu et al.

    Life Sci.

    (1983)
  • J.A. Nielsen

    Neuropharmacology

    (1985)
  • P. Kalix

    Life Sci.

    (1983)
  • A.N. Guantai et al.

    Neuropharmacology

    (1987)
  • J.L. Zelger et al.

    Pharmacol., Biochem. Behav.

    (1980)
  • P. Nencini

    Pharmacol., Biochem. Behav.

    (1988)
    P. Nencini

    macol. Exp. Ther.

    (1988)
  • R.W. Foltin et al.

    J. Pharmacol. Exp. Ther.

    (1983)
  • R.W. Foltin et al.

    Pharmacol., Biochem. Behav.

    (1981)
  • A.J. Goudie et al.

    Psychopharmacology

    (1985)
  • P.B. Dews

    J. Pharmacol. Exp. Ther.

    (1958)
  • E.A. Babayan et al.

    Drug Alcohol Depend.

    (1983)
  • W.L. Woolverton et al.

    J. Exp. Anal. Behav.

    (1984)
  • M.D. Schechter

    Pharmacol., Biochem. Behav.

    (1986)
  • D. Huang et al.

    Pharmacol., Biochem. Behav.

    (1986)
  • A.J. Goudie et al.

    Neuropharmacology

    (1986)
  • M.D. Schechter

    Pharmacol., Biochem. Behav.

    (1986)
  • P. Nencini et al.

    Pharmacol. Res. Commun.

    (1982)
  • P. Nencini et al.

    Pharmacology

    (1984)
  • M. Moscucci et al.
  • R. Gugelman et al.

    Experientia

    (1985)
  • N. Abdul Ghani et al.

    Soc. Sci. Med.

    (1987)
  • P. Nencini

    Pharmacol. Res., Commun.

    (1980)
  • P. Kalix

    J. Pharm. Pharmacol.

    (1980)
  • WHO Expert Committee on Drug Dependence

    Twenty-second Report

  • P. Nencini et al.

    Clin. Ter.

    (1978)
  • T. Baasher et al.

    The epidemiology of Khat

  • Bull. Narc.

    (1980)
  • Bull. Narc.

    (1980)
  • H. Halbach

    WHO Bull.

    (1972)
  • P. Kalix et al.

    Pharmacol. Rev.

    (1984)
  • R. Brenneisen et al.

    Pharm. Acta Helv.

    (1985)
  • R. Brenneisen et al.

    Planta Med.

    (1984)
  • L. Crombie

    Bull. Narc.

    (1980)
  • I.A. Al-Meshal et al.

    Agents Actions

    (1985)
  • Cited by (0)

    Supported by a grant from the United Nations' Fund for Drug Abuse Control.

    View full text